UK / Pharma Industry Warns of Declining Competitiveness
The UK government has decided to go ahead with a much-debated increase in the revenue clawback rate —from 24.4 percent to 27.5 percent— for drugmakers subject to its Statutory Scheme…
Address: No. 2, 32 Caxton Road,
Shepherd’s Bush, London W12 8AJ,United Kingdom
Tel: +44 (0)20 ‐ 7229 4552
Web: http://www.dwlanguages.com/page.asp?node=2
DWL is a specialist translation service provider for the pharmaceutical industry providing Medical Translation into all European Union (EU) and European Economic Area (EEA) languages and many others – mainly “from” and “into” English
Established in 1962, our business has grown through dedication and commitment to quality and service. This is acknowledged by our many long-standing clients and is perhaps most clearly demonstrated by their recommendation of DWL to others.
By recognising the specific needs of this market, DWL delivers a quality Medical Translation Service due to its expertise in selecting the most suitable linguists in combination with reliable project management and quality control. We understand the need to be flexible and responsive in our service, and that accuracy and thoroughness remain essential – even within the tightest of project timelines.
DW Languages provides translation solutions for the following areas:
Medical translation services
Pharmaceutical translation
Regulatory affairs
Clinical trials
Medical research and manufacturing
Legal documentation
Medical publishing and marketing communications
The UK government has decided to go ahead with a much-debated increase in the revenue clawback rate —from 24.4 percent to 27.5 percent— for drugmakers subject to its Statutory Scheme…
Dr Matt Linley, senior director for analytics and forecasting at predictive health analytics firm Airfinity, looks ahead to a potentially game-changing year in the fight against respiratory synctial virus (RSV),…
A roundup of the latest UK healthcare, pharma and biotech news including AbbVie and Lilly’s departure from the country’s voluntary medicines pricing agreement, Moderna’s expanded footprint, UK biotech’s 2022 funding…
What digital skills do pharma leaders need in order to drive transformation, deliver success at scale in the business, and prepare for next-gen customer engagement? Sarah Gilchriest explores the critical…
Bernard Ross, a serial entrepreneur with more than 20 years’ senior experience at private and public board level across multiple industries, looks ahead to 2023 and highlights five key trends…
After an almost 20-year career in Big Pharma culminating in a role as president of AstraZeneca UK, Lisa Anson took the leap into the biotech world to lead what at…
Pricing and market access have become increasingly hot topics in recent years, as healthcare systems across the world attempt to balance their own financial sustainability with securing the latest medical…
National Health Service (NHS) England CEO Amanda Pritchard has raised concerns about the state of British healthcare in recent weeks and months, proclaiming that the NHS is in a worse…
With the brief tenure of Liz Truss as Prime Minister already drawing to a close, the UK faces yet another new leader as the country attempts to extricate itself from…
“Life sciences are at the heart of my vision to build a country fit for the future,” tweeted new UK Prime Minister Liz Truss last month. Now installed as leader…
US biotech Moderna – producer of a messenger RNA (mRNA) COVID-19 vaccine that has found its way into 75 million arms in the US alone and generated USD 12 billion…
After several scandals that revealed longstanding deficiencies and a continual churn of executive staff, a recent independent review of leadership in the National Health Service (NHS) has uncovered a lack…
See our Cookie Privacy Policy Here